Terms ending in 2040

The Institut Pasteur

Every in-force patent on The Institut Pasteur's record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.

Patent	Title	Holder	Status	Expires	Confidence
US 11,680,245	Human Innate Lymphoid Cell Precursors: Identification, Characterization, Applications Institut Pasteur In force Term ends Feb 1, 2040 · High confidence	Institut Pasteur	In force	Term ends Feb 1, 2040	High confidence
US 11,643,625	Hydrogel-Based Organ-On-Chip Microfluidic Device Institut Pasteur In force Term ends Feb 21, 2040 · High confidence	Institut Pasteur	In force	Term ends Feb 21, 2040	High confidence
US 11,001,901	METHODS AND REAGENTS FOR THE SPECIFIC AND SENSITIVE DETECTION OF SARS-CoV-2 Institut Pasteur In force Term ends Mar 5, 2040 · High confidence	Institut Pasteur	In force	Term ends Mar 5, 2040	High confidence
US 10,948,490	Severe Acute Respiratory Syndrome (SARS) - Associated Coronavirus Diagnostics Institut Pasteur In force Term ends Jul 23, 2040 · High confidence	Institut Pasteur	In force	Term ends Jul 23, 2040	High confidence
US 11,815,513	Severe Acute Respiratory Syndrome (SARS) - Associated Coronavirus Diagnostics Institut Pasteur In force Term ends Jul 23, 2040 · High confidence	Institut Pasteur	In force	Term ends Jul 23, 2040	High confidence
US 12,326,451	Severe Acute Respiratory Syndrome (SARS) - Associated Coronavirus Diagnostics Institut Pasteur In force Term ends Jul 23, 2040 · High confidence	Institut Pasteur	In force	Term ends Jul 23, 2040	High confidence
US 12,188,057	Primer-Independent DNA Polymerases and Their Use for DNA Synthesis Institut Pasteur In force Term ends Oct 3, 2040 · High confidence	Institut Pasteur	In force	Term ends Oct 3, 2040	High confidence

7 of 7 patents shown. Soonest term end first, then patent number.

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.